{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:54:31Z","timestamp":1791312871986,"version":"4.3.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"University of Ottawa Clinical Research Chair Award"},{"name":"Children\u2019s Hospital of Eastern Ontario Research Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-023-01065-4","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T08:03:14Z","timestamp":1677830594000},"page":"613-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI"],"prefix":"10.1007","volume":"112","author":[{"given":"Emily","family":"Seale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ochoa","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Carsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holden","family":"Sheffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaldoun","family":"Koujok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Eve","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Feber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor N.","family":"Konji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-4319","authenticated-orcid":false,"given":"Leanne M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"6","key":"1065_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00223-016-0110-1","volume":"98","author":"LM Ward","year":"2016","unstructured":"Ward LM, Bardai G, Moffatt P, Al-Jallad H, Trejo P, Glorieux FH, Rauch F (2016) Osteogenesis imperfecta type VI in individuals from Northern Canada. Calcif Tissue Int 98(6):566\u2013572. https:\/\/doi.org\/10.1007\/s00223-016-0110-1","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"1065_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17(1):30\u201338. https:\/\/doi.org\/10.1359\/jbmr.2002.17.1.30","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00198-017-4141-x","volume":"28","author":"P Trejo","year":"2017","unstructured":"Trejo P, Palomo T, Montpetit K, Fassier F, Sato A, Glorieux FH, Rauch F (2017) Long-term follow-up in osteogenesis imperfecta type VI. Osteoporos Int 28(10):2975\u20132983. https:\/\/doi.org\/10.1007\/s00198-017-4141-x","journal-title":"Osteoporos Int"},{"issue":"4","key":"1065_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677\u2013692. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020","journal-title":"Bone"},{"issue":"1","key":"1065_CR5","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo P, Rauch F, Ward LM (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18(1):76\u201380","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"1065_CR6","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O (2016) Safety and efficacy of denosumab in children with osteogenesis imperfecta: a first prospective trial. J Musculoskelet Neuronal Interact 16(1):24\u201332","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"3","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","volume":"40","author":"C Land","year":"2007","unstructured":"Land C, Rauch F, Travers R, Glorieux FH (2007) Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 40(3):638\u2013644. https:\/\/doi.org\/10.1016\/j.bone.2006.10.010","journal-title":"Bone"},{"issue":"2","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s8756-3282(99)00257-4","volume":"26","author":"FH Glorieux","year":"2000","unstructured":"Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM (2000) Normative data for iliac bone histomorphometry in growing children. Bone 26(2):103\u2013109. https:\/\/doi.org\/10.1016\/s8756-3282(99)00257-4","journal-title":"Bone"},{"issue":"5","key":"1065_CR9","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald MM, Khoo WH, Ng PY, Xiao Y, Zamerli J, Thatcher P, Kyaw W, Pathmanandavel K, Grootveld AK, Moran I et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184(5):1330-1347.e13. https:\/\/doi.org\/10.1016\/j.cell.2021.02.002","journal-title":"Cell"},{"issue":"4","key":"1065_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","volume":"15","author":"AM Boyce","year":"2017","unstructured":"Boyce AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15(4):283\u2013292. https:\/\/doi.org\/10.1007\/s11914-017-0380-1","journal-title":"Curr Osteoporos Rep"},{"issue":"11","key":"1065_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00198-021-06002-5","volume":"32","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Doulgeraki A, Polyzos SA, Guarnieri V, Papapoulos SE (2021) Denosumab for the treatment of primary pediatric osteoporosis. Osteoporos Int 32(11):2377\u20132381. https:\/\/doi.org\/10.1007\/s00198-021-06002-5","journal-title":"Osteoporos Int"},{"key":"1065_CR12","doi-asserted-by":"publisher","first-page":"101148","DOI":"10.1016\/j.bonr.2021.101148","volume":"15","author":"K Horiuchi","year":"2021","unstructured":"Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K (2021) Hypercalcemia following discontinuation of denosumab therapy: a systematic review. Bone Rep 15:101148. https:\/\/doi.org\/10.1016\/j.bonr.2021.101148","journal-title":"Bone Rep"},{"issue":"5","key":"1065_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12519-020-00378-w","volume":"16","author":"C Sydlik","year":"2020","unstructured":"Sydlik C, D\u00fcrr HR, Pozza SBD, Wei\u00dfenbacher C, Roeb J, Schmidt H (2020) Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention? World J Pediatr 16(5):520\u2013527. https:\/\/doi.org\/10.1007\/s12519-020-00378-w","journal-title":"World J Pediatr"},{"issue":"4","key":"1065_CR14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, T\u00f6rring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res 28(4):746\u2013752. https:\/\/doi.org\/10.1002\/jbmr.1808","journal-title":"J Bone Miner Res"},{"key":"1065_CR15","doi-asserted-by":"publisher","first-page":"116395","DOI":"10.1016\/j.bone.2022.116395","volume":"159","author":"JA Vanderniet","year":"2022","unstructured":"Vanderniet JA, Wall CL, Mullins A, London K, Lim L, Hibbert S, Briody J, Padhye B, Poon M, Biggin A, Dalla-Pozza L, Munns CF (2022) Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre. Bone 159:116395. https:\/\/doi.org\/10.1016\/j.bone.2022.116395","journal-title":"Bone"},{"issue":"7","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36(7):1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Miner Res"},{"key":"1065_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"issue":"1","key":"1065_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152. https:\/\/doi.org\/10.3390\/jcm10010152","journal-title":"J Clin Med"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-023-01065-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T12:03:39Z","timestamp":1681646619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-023-01065-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s00223-023-01065-4","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LMW has participated in clinical trials with ReveraGen, Ascendis, PTC, Catabasis, Novartis, Ultragenyx and Amgen, received unrestricted educational grants from Alexion, Ipsen and Ultragenyx, and received consulting fees from Santhera, Ipsen, Ultragenyx, PTC, Novartis, and Amgen (with funds to LMW's institution). MER has participated in clinical trials with Amgen (with funds to MER\u2019s institution). SC has received research grant funding from Zimmer Biomet and ConMed Linvatec, consulting fees for assisting with surgical training from Stryker and Smith & Nephew, and has participated in a clinical trial with Ascendis Biopharma (with Funds to SC\u2019s institution). KS has consulted for Medtronic and has received research grants from Meditronics, Ascendis and SpinoModulation (all funds to KS\u2019s institution). FR has been a consultant to Sanofi and Ultragenyx, received research grants from MITACS and Mereo BioPharma and a study grant from Ultragenyx, Catabasis, PreciThera (all funds to FR\u2019s institution). The other co-authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study that involved human participant were in accordance with the 1964 Helsinki Declaration and its later amendments. Written consent was obtained from the patient\u2019s caregiver in line with the Children\u2019s Hospital of Eastern Ontario Research Institute ethical requirements. Written consent was obtained from the patient\u2019s caregiver in line with the Children\u2019s Hospital of Eastern Ontario Research Institute ethical requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Informed Consent"}}]}}